Back to results
US 10,328,151 B2Granted
Anti-methanogenic compositions and uses thereof
AssigneeCedars-Sinai Medical Center
InventorsMark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
Life of this patent
Estimating the term…
Abstract
The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
Claims21
A pharmaceutical formulation, comprising at least two types of modified-release particles, each modified-release particle containing:
- about 5-20% by weight antimethanogenic statin;
- about 50-70% by weight microcrystalline cellulose;
- about 1-10% by weight copovidone;
- about 0.1-3.0% by weight silicon dioxide;
- about 0.1-3.0% by weight magnesium stearate;
- about 1-10% by weight crospovidone;
- and
- about 10-20% by weight enteric polymer;
- wherein a first type of modified-release particle comprises a first enteric polymer that dissolves at a pH of about 5.5 and a second type of modified-release particle comprises a second enteric polymer that dissolves at a pH of about 7.0,
- wherein the systemic absorption of the antimethanogenic statin is insufficient to provide a clinically effective reduction in cholesterol, and
- wherein the formulation has a unit dosage of about 21 to 42 mg of the antimethanogenic statin.
8 more elements
Dependencies are inferred from the claim text.